Chronic Rejection Series: Heart Cardiac Allograft Vasculopathy

异基因识别 免疫学 免疫系统 医学 移植 主要组织相容性复合体 获得性免疫系统 抗原 心脏移植 T细胞 炎症 自身抗体 生物 抗体 内科学
作者
Michael Rheaume,Natasha Aleksova,Joren C. Madsen,Gilles Bénichou
出处
期刊:Transplantation [Wolters Kluwer]
卷期号:110 (1): e28-e41 被引量:4
标识
DOI:10.1097/tp.0000000000005453
摘要

Cardiac allograft vasculopathy (CAV) is a leading contributor to late allograft failure, mortality, and morbidity after heart transplantation. The prevalence of moderate to severe CAV over time has not changed significantly, and CAV remains an important contemporary consideration in post-heart transplantation management. The diagnosis and surveillance of CAV include both established and emerging invasive and noninvasive modalities, with a growing interest in understanding microvascular function and coronary physiology. The management of CAV is primarily focused on the prevention of CAV progression and optimizing traditional cardiovascular risk factors. Although mammalian target of rapamycin inhibitors and statins are central to the prevention of CAV progression, there is a lack of novel therapeutics for CAV. The development of new therapies for CAV will require a better understanding of the immune mechanisms underlying the initiation and perpetuation of this condition. CAV is mediated through a complex process involving cells and soluble factors of both innate and adaptive immune systems. Animal studies demonstrated that T cells play a central role in CAV. Both alloreactive T cells, which recognize donor major histocompatibility complex peptides (indirect allorecognition), and autoreactive T cells directed against heart tissue-specific antigens such as cardiac myosin have been shown to trigger CAV in mice. These processes involve the production of donor-specific antibodies and autoantibodies, respectively. Other studies suggest that CAV could be mediated by bystander T cells in a T cell receptor-independent manner and that CAV requires cooperation between T cells and natural killer cells. In addition, the essential role of interferon-γ in CAV has been documented. Whether any of these mechanisms pertain to CAV observed in transplanted patients has not been thoroughly investigated. Gaining insights into this question will be instrumental to the design of immune-based therapies for CAV.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
JIn完成签到,获得积分10
2秒前
慕青的应助被星空采纳,获得10
3秒前
3秒前
朴艺晨完成签到 ,获得积分10
4秒前
Full完成签到,获得积分10
4秒前
天天快乐的应助被峰峰采纳,获得10
4秒前
4秒前
洛玥完成签到 ,获得积分10
5秒前
鄂老三完成签到,获得积分10
5秒前
山复尔尔完成签到,获得积分10
5秒前
6秒前
做文章要专心完成签到 ,获得积分10
6秒前
理想红猪发布了新的文献求助10
7秒前
zzi发布了新的文献求助10
7秒前
厉奕欣完成签到 ,获得积分10
8秒前
janeli完成签到 ,获得积分10
8秒前
wangweisky发布了新的文献求助10
8秒前
xh93完成签到,获得积分10
9秒前
Mia完成签到,获得积分10
9秒前
妍三微月完成签到 ,获得积分10
9秒前
10秒前
10秒前
e2r完成签到,获得积分10
10秒前
zhu1230完成签到,获得积分10
10秒前
11秒前
连夏之完成签到,获得积分10
11秒前
LiLi完成签到,获得积分10
12秒前
12秒前
12秒前
StarXG完成签到,获得积分10
13秒前
sortie发布了新的文献求助30
13秒前
安静柚子发布了新的文献求助10
13秒前
123发布了新的文献求助30
14秒前
星空发布了新的文献求助10
15秒前
狄俄尼索斯完成签到,获得积分10
15秒前
情怀的应助被Nicole采纳,获得10
15秒前
大个的应助被youngfer采纳,获得10
15秒前
15秒前
FF完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186261
求助须知:如何正确求助?哪些是违规求助? 9574697
关于积分的说明 21837731
捐赠科研通 7783915
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559109
邀请新用户注册赠送积分活动 2481528